AI-generated summary
The authors followed 120 early breast cancer patients who had received photobiomodulation or placebo during radiotherapy, retrospectively, for a median of 66 months. They report no significant difference between the groups in disease-free, cancer-free or overall survival. The authors state that their results suggest photobiomodulation does not influence locoregional recurrence, new primary tumors or overall survival.
- Participants
- 120
- Who or what was studied
- Early-stage breast cancer patients undergoing conventional fractionation radiotherapy, 60 treated with photobiomodulation and 60 with placebo
- Wavelengths
- 808, 905 nm
- Limits stated in the abstract
- The study was retrospective and analyzed clinical data from a single trial cohort, with survival differences not statistically significant.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808-905 nm
- Energy density (fluence)
- 4 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.